Immune checkpoint blockade in malignant mesothelioma A novel therapeutic strategy against a deadly disease?

被引：10

作者：

Calabro, Luana ^{[1
]}

Maio, Michele ^{[1
]}

机构：

[1] Univ Hosp Siena, Ist Toscano Tumori, Siena, Italy

来源：

ONCOIMMUNOLOGY | 2014年 / 3卷 / 01期

关键词：

anti-CTLA4; antibody; mesothelioma; tremelimumab; immunomodulating antibody; therapy; PLEURAL MESOTHELIOMA; IMMUNOTHERAPY; CHEMOTHERAPY; CRITERIA;

D O I：

10.4161/onci.27482

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 [肿瘤学];

摘要：

Monoclonal antibodies that target immune checkpoints are undoubtedly changing the therapeutic landscape of different human malignancies. Here we comment on the effects of blocking cytotoxic T lymphocyte-associated protein 4 (CTLA4) by means of the monoclonal antibody tremelimumab in patients with refractory malignant mesothelioma, a deadly disease with no effective therapeutic options.

引用

收藏

页数：2

相关论文

共 10 条

[1]

Modified RECIST criteria for assessment of response in malignant pleural mesothelioma [J].

Byrne, MJ ;

Nowak, AK .

ANNALS OF ONCOLOGY, 2004, 15 (02) :257-260

[2]

Biomarkers for immune checkpoint inhibitors Reply [J].

Calabro, Luana ;

Maio, Michele .

LANCET ONCOLOGY, 2014, 15 (01) :E1-E2

[3]

Tremelimumab for patients with chemotherapy-resistant advanced malignant mesothelioma: an open-label, single-arm, phase 2 trial [J].

Calabro, Luana ;

Morra, Aldo ;

Fonsatti, Ester ;

Cutaia, Ornella ;

Amato, Giovanni ;

Giannarelli, Diana ;

Di Giacomo, Anna Maria ;

Danielli, Riccardo ;

Altomonte, Maresa ;

Mutti, Luciano ;

Maio, Michele .

LANCET ONCOLOGY, 2013, 14 (11) :1104-1111

[4]

Clinical Studies With Anti-CTLA-4 Antibodies in Non-melanoma Indications [J].

Calabro, Luana ;

Danielli, Riccardo ;

Sigalotti, Luca ;

Maio, Michele .

SEMINARS IN ONCOLOGY, 2010, 37 (05) :460-467

[5]

Long-term survival and immunological parameters in metastatic melanoma patients who responded to ipilimumab 10 mg/kg within an expanded access programme [J].

Di Giacomo, Anna Maria ;

Calabro, Luana ;

Danielli, Riccardo ;

Fonsatti, Ester ;

Bertocci, Erica ;

Pesce, Isabella ;

Fazio, Carolina ;

Cutaia, Ornella ;

Giannarelli, Diana ;

Miracco, Clelia ;

Biagioli, Maurizio ;

Altomonte, Maresa ;

Maio, Michele .

CANCER IMMUNOLOGY IMMUNOTHERAPY, 2013, 62 (06) :1021-1028

[6]

Immunotherapy and the concept of a clinical cure [J].

Eggermont, Alexander M. M. ;

Kroemer, Guido ;

Zitvogel, Laurence .

EUROPEAN JOURNAL OF CANCER, 2013, 49 (14) :2965-2967

[7]

New checkpoint inhibitors ride the immunotherapy tsunami [J].

Mullard, Asher .

NATURE REVIEWS DRUG DISCOVERY, 2013, 12 (07) :489-+

[8]

Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma [J].

Vogelzang, NJ ;

Rusthoven, JJ ;

Symanowski, J ;

Denham, C ;

Kaukel, E ;

Ruffie, P ;

Gatzemeier, U ;

Boyer, M ;

Emri, S ;

Manegold, C ;

Niyikiza, C ;

Paoletti, P .

JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (14) :2636-2644

[9]

Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria [J].

Wolchok, Jedd D. ;

Hoos, Axel ;

O'Day, Steven ;

Weber, Jeffrey S. ;

Hamid, Omid ;

Lebbe, Celeste ;

Maio, Michele ;

Binder, Michael ;

Bohnsack, Oliver ;

Nichol, Geoffrey ;

Humphrey, Rachel ;

Hodi, F. Stephen .

CLINICAL CANCER RESEARCH, 2009, 15 (23) :7412-7420

[10]

Second-line chemotherapy in malignant pleural mesothelioma: Results of a retrospective multicenter survey [J].

Zucali, P. A. ;

Simonelli, M. ;

Michetti, G. ;

Tiseo, M. ;

Ceresoli, G. L. ;

Collova, E. ;

Follador, A. ;

Lo Dico, M. ;

Moretti, A. ;

De Vincenzo, F. ;

Lorenzi, E. ;

Perrino, M. ;

Giordano, L. ;

Farina, G. ;

Santoro, A. ;

Garassino, M. .

LUNG CANCER, 2012, 75 (03) :360-367